Esperion Therapeutics (ESPR) to Release Earnings on Tuesday

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) is anticipated to issue its Q1 2025 quarterly earnings data before the market opens on Tuesday, May 6th. Analysts expect the company to announce earnings of ($0.18) per share and revenue of $54.97 million for the quarter.

Esperion Therapeutics Price Performance

Shares of ESPR stock traded down $0.02 during trading on Thursday, hitting $0.98. 3,151,909 shares of the stock traded hands, compared to its average volume of 5,664,948. The firm has a market capitalization of $194.98 million, a P/E ratio of -1.54 and a beta of 0.86. The firm's fifty day moving average price is $1.34 and its 200-day moving average price is $1.94. Esperion Therapeutics has a 52-week low of $0.82 and a 52-week high of $3.94.

Analyst Ratings Changes

Several analysts recently weighed in on ESPR shares. JMP Securities reiterated a "market outperform" rating and issued a $4.00 target price (down previously from $7.00) on shares of Esperion Therapeutics in a report on Tuesday, February 11th. Needham & Company LLC reiterated a "buy" rating and issued a $5.00 target price on shares of Esperion Therapeutics in a report on Friday, April 25th. HC Wainwright reiterated a "buy" rating and issued a $16.00 target price on shares of Esperion Therapeutics in a report on Friday, April 25th. Finally, The Goldman Sachs Group dropped their target price on shares of Esperion Therapeutics from $4.00 to $3.00 and set a "neutral" rating for the company in a report on Thursday, April 17th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $6.42.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.